Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of “Moderate Buy” by Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $28.6667.

Several research analysts have commented on KYTX shares. Wall Street Zen raised shares of Kyverna Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Wells Fargo & Company upped their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Finally, HC Wainwright boosted their target price on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 27th.

Insider Buying and Selling at Kyverna Therapeutics

In other Kyverna Therapeutics news, CTO Karen Marie Walker sold 23,998 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $12.20, for a total value of $292,775.60. Following the transaction, the chief technology officer owned 22,636 shares of the company’s stock, valued at $276,159.20. This represents a 51.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Beth C. Seidenberg bought 133,333 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the director owned 869,317 shares of the company’s stock, valued at approximately $6,519,877.50. The trade was a 18.12% increase in their position. The disclosure for this purchase is available in the SEC filing.

Hedge Funds Weigh In On Kyverna Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc raised its stake in shares of Kyverna Therapeutics by 179.5% during the second quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock valued at $774,000 after acquiring an additional 161,954 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Kyverna Therapeutics during the 2nd quarter worth $129,000. Ethic Inc. purchased a new position in Kyverna Therapeutics during the 2nd quarter worth $56,000. Phoenix Wealth Advisors bought a new stake in Kyverna Therapeutics during the 2nd quarter valued at $32,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of Kyverna Therapeutics in the 2nd quarter worth $37,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Trading Down 7.1%

KYTX opened at $9.76 on Monday. The stock has a 50-day moving average of $8.36 and a 200 day moving average of $6.23. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $13.67. The firm has a market cap of $427.49 million, a P/E ratio of -2.62 and a beta of 3.45.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12. On average, research analysts forecast that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.